Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans<sup>1</sup>

Ladabaum, Uri; Glidden, David V.

doi:10.1046/j.1365-2982.2002.00344.x

Cited by 40 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, case series show that more than one third of patients with gastroparesis receive at least one antidepressant [6, 8, 10], leaving fewer options to modify their medical therapy. Several agents have been tested in healthy volunteers with mixed results on postprandial symptoms [181–183]. A small retrospective study suggested significant improvement in about half of the patients [184].…”

Section: Treatmentmentioning

confidence: 99%

Gastroparesis: Concepts, Controversies, and Challenges

Bielefeldt

2012

Scientifica

View full text Add to dashboard Cite

Patients with gastroparesis often present a challenge to the treating physician. Postprandial symptoms with nausea and vomiting may not only lead to nutritional and metabolic consequences, but also cause significant disruptions to social activities that often center around food. While the definition of gastroparesis focuses on impaired gastric emptying, treatment options that affect gastric function are limited and often disappointing. The female predominance, the mostly idiopathic nature of the illness with a common history of abuse, and coexisting anxiety or depression show parallels with other functional disorders of the gastrointestinal tract. These parallels provided the rationale for some initial studies investigating alternative therapies that target the brain rather than the stomach. This emerging shift in medical therapy comes at a time when clinical studies suggest that gastric electrical stimulation may exert its effects by modulating visceral sensory processing rather than altering gastric motility. Physiologic and detailed anatomic investigations also support a more complex picture with different disease mechanisms, ranging from impaired accommodation to apparent visceral hypersensitivity or decreased interstitial cells of Cajal to inflammatory infiltration of myenteric ganglia. Delayed gastric emptying remains the endophenotype defining gastroparesis. However, our treatment options go beyond prokinetics and may allow us to improve the quality of life of affected individuals.

show abstract

Section: Treatmentmentioning

confidence: 99%

Gastroparesis: Concepts, Controversies, and Challenges

Bielefeldt

2012

Scientifica

View full text Add to dashboard Cite

show abstract

“…Sertraline had no effect on gastric sensitivity or compliance, or somatic pain tolerance in healthy humans in one study [Ladabaum and Glidden, 2002]. Pretreatment with paroxetine did not alter the thresholds for perception and discomfort during barostat distention, but significantly enhanced the amplitude of meal-induced fundus relaxation on healthy volunteers.…”

Section: Visceral Hypersensitivity and Central Pain Perceptionmentioning

confidence: 87%

Review: Functional dyspepsia

Brun

Kuo

2010

Therap Adv Gastroenterol

109

View full text Add to dashboard Cite

Dyspepsia is a common term used for a heterogeneous group of abdominal symptoms. Functional dyspepsia (FD) is the focus of this review. The 2006 Rome III criteria defined FD and its subgroups, postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). FD is a very common condition with a high prevalence throughout the world, adversely affecting the quality of life of patients. The pathophysiology of FD has been under investigation during the past two decades. Multiple mechanisms such as abnormal gastric emptying, visceral hypersensitivity, impaired gastric accommodation, and central nervous system factors are likely involved. Several tests are available for the assessment of various physiologic functions possibly involved in the pathogenesis of FD, and some of these could be used in clinical practice, helping to understand the abnormalities underlining patients' complaints. Currently, the possibilities of pharmacological therapy for FD are still limited, however, experience of using prokinetics, tricyclic antidepressants, selective serotonin-reuptake inhibitors (SSRIs), proton-pump inhibitors (PPIs), and several alternative techniques has been accumulated. The different combinations of alterations in physiologic gastrointestinal and central nervous system functions result in the very heterogeneous nature of FD so combined approaches to these patients could be beneficial in challenging cases.

show abstract